Barinthus Biotherapeutics/BRNS

$2.64

-15.85%
-
1D1W1MYTD1YMAX

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

Ticker

BRNS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Enright

Employees

130

Headquarters

Didcot, United Kingdom

BRNS Metrics

BasicAdvanced
$122.21M
Market cap
-
P/E ratio
-$1.91
EPS
-
Beta
-
Dividend rate
$122.21M
$5.10
$1.64
21.6K
12.455
-30.31%
-34.14%
-31.98%
152.385
0.65
0.818
-98.21%
-1,599.09%
-45%

What the Analysts think about BRNS

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
180.3% upside
High $12.00
Low $3.00
$2.64
Current price
$7.40
Average price target

BRNS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-17.2M
22.86%
Profit margin
0%
-

BRNS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.89%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.48
-$0.62
-$0.37
-$0.45
-
Expected
-$0.50
-$0.55
-$0.53
-$0.50
-$0.54
Surprise
-4.64%
13.35%
-30.19%
-9.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Barinthus Biotherapeutics stock?

Barinthus Biotherapeutics (BRNS) has a market cap of $122.21M as of April 16, 2024.

What is the P/E ratio for Barinthus Biotherapeutics stock?

The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of April 16, 2024.

Does Barinthus Biotherapeutics stock pay dividends?

No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Barinthus Biotherapeutics dividend payment date?

Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.

What is the beta indicator for Barinthus Biotherapeutics?

Barinthus Biotherapeutics (BRNS) does not currently have a Beta indicator.

What is the Barinthus Biotherapeutics stock price target?

The target price for Barinthus Biotherapeutics (BRNS) stock is $7.4, which is 180.3% above the current price of $2.64. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Barinthus Biotherapeutics stock

Buy or sell Barinthus Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing